Adam J. Gadzinksi, MD, MS, on the Impact of Telemedicine on Patient-Reported Outcomes

Video

The study assessed the impact of a rurally focused telemedicine program on patient outcomes in the urologic oncology outpatient clinic at the University of Washington Medical Center.

Findings from a study presented at the Society of Urologic Oncology 21st Annual Meeting revealed the impact of a rurally focused telemedicine program on patient outcomes in the urologic oncology outpatient clinic at the University of Washington Medical Center (UWMC).

The investigators ultimately discovered that telemedicine provides a medium for cancer care delivery that eliminates the significant travel burden associated with in-person clinic appointments.

In an interview with CancerNetwork®, Adam J. Gadzinski, MD, MS, urologic oncology fellow and an acting instructor of Urologic Oncology at the Urology Clinic at UWMC, explained the implications of these study results.

Transcription:

I think for us, what we really took out of this was that patients were spending a lot just to come and see us in clinic. And that telemedicine, in terms of at least the outcomes of patient satisfaction, really was equivalent to in person visits. We had very complex discussions about very challenging cancer issues and decisions that patients had to make. And I think we found that having those discussions over telemedicine was pretty darn similar to in person visits.

And for certain parts of urologic cancer care, physical exam is not always the kind of hinge point of a decision and so you don't have to examine someone when you have their CT scan that you can review with them. You know, maybe they don't need to drive from eastern Washington 5 hours for you to, to you know, lay your hands on their abdomen and then look at the CT scan with them and make all of your cancer treatment decisions based on the CT scan.

There are some patients you do have to kind of see them in person and examine them in person before you decide on treatment decisions. And sometimes what we found is the telemedicine really streamlined their in person visit when they did come, so then when they come they're also getting, you know, a repeat CT scan, they’re getting labs, and so their trip to Washington, to Seattle, was more of a implementing a plan and less kind of discovering what that plan might be.

Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content